{"id":34314,"date":"2022-09-21T11:54:10","date_gmt":"2022-09-21T03:54:10","guid":{"rendered":"http:\/\/biopioneer.com.tw\/?p=34314"},"modified":"2025-11-15T16:14:31","modified_gmt":"2025-11-15T08:14:31","slug":"17-dmag-alvespimycin-hcl-cas467214-21-7-apexbio-%e8%b2%a8%e8%99%9fa2213","status":"publish","type":"post","link":"http:\/\/biopioneer.com.tw\/?p=34314","title":{"rendered":"17-DMAG (Alvespimycin) HCl | CAS#467214-21-7 APExBIO \u8ca8\u865fA2213"},"content":{"rendered":"

\u86cb\u767d\u9176(Proteases)\u7cfb\u5217\u5546\u54c1->>17-DMAG (Alvespimycin) HCl<\/span><\/span><\/span><\/span><\/strong><\/p>\n

APExBIO Technology LLC \u662f\u4e00\u5bb6\u9818\u5148\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5291 (Small Molecule Inhibitors)\/\u6d3b\u5316\u5291(Activators)\u3001\u5316\u5408\u7269\u5eab( Compound Libraries)\u3001\u80dc\u80bd(Peptides)\u3001\u6aa2\u6e2c\u8a66\u5291\u76d2(Assay Kits)\u3001\u87a2\u5149\u6a19\u8a18(Fluorescent Label)\u3001\u9176(Enzymes)\u3001\u4fee\u98fe\u6838\u82f7\u9178(Modified Nucleotides)\u3001mRNA \u5408\u6210\u4ee5\u53ca\u5404\u7a2e\u5206\u5b50\u751f\u7269\u5b78\u5de5\u5177\u7684\u4f9b\u61c9\u5546\u3002APExBIO\u63d0\u4f9b\u5ee3\u6cdb\u7684\u7522\u54c1\u7dda\uff0c\u6db5\u84cb 20 \u591a\u500b\u4e0d\u540c\u7684\u7814\u7a76\u9818\u57df\uff0c\u4f8b\u5982\u764c\u75c7(cancer)\u3001\u514d\u75ab\u5b78(immunology)\u3001\u795e\u7d93\u79d1\u5b78(neurosciences)\u3001\u7d30\u80de\u51cb\u4ea1(apoptosis)\u548c\u8868\u89c0\u907a\u50b3\u5b78(epigenetics)\u7b49\u3002\u516c\u53f8\u7e3d\u90e8\u4f4d\u65bc\u7f8e\u570b\u5fb7\u5dde\u4f11\u58eb\u9813USA (Houston, Texas)\uff0c\u81f4\u529b\u65bc\u670d\u52d9\u5168\u7403\u5ba2\u6236\u3002\u9ad8\u5ea6\u91cd\u8996\u7522\u54c1\u54c1\u8cea\u3002\u6240\u6709\u7522\u54c1\u5747\u9075\u5faa\u56b4\u683c\u7684\u751f\u7522\u6307\u5357\uff0c\u4e26\u9644\u6709\u5206\u6790\u8b49\u66f8\u3001HPLC\u3001\u8cea\u8b5c(Mass Spectrum)\u548cHMNR\u4ee5\u53ca\u9ad4\u5916\u9a57\u8b49(in vitro validation)\u3002 APExBIO\u7522\u54c1\u5df2\u88ab\u300aNature\u300b\u3001\u300aCell\u300b\u548c\u300aScience\u300b\u7b49\u773e\u591a\u9802\u7d1a\u540c\u884c\u8a55\u5be9\u671f\u520a\u5f15\u7528\u3002>>\u66f4\u591aAPExBio\u5546\u54c1<\/span><\/strong><\/em><\/span><\/a><\/p>\n

<\/p>\n

\u86cb\u767d\u9176(Proteases)\u4e5f\u7a31\u70ba\u80bd\u9176(peptidases)\u6216\u86cb\u767d\u6c34\u89e3\u9176(proteolytic enzymes)\uff0c\u7531\u5927\u91cf\u50ac\u5316\u80bd\u9375\u6c34\u89e3(hydrolysis)\u4e26\u96a8\u5f8c\u5c0e\u81f4\u86cb\u767d\u8cea\u5e95\u7269(protein substrates)\u964d\u89e3\u70ba\u6c28\u57fa\u9178(amino acids)\u7684\u9176\u7d44\u6210\u3002\u86cb\u767d\u9176(Proteases)\u8207\u591a\u7a2e\u4eba\u985e\u75be\u75c5\u6709\u95dc\uff0c\u5305\u62ec\u764c\u75c7(cancer)\u3001\u795e\u7d93\u9000\u884c\u6027\u75be\u200b\u200b\u75c5(neurodegenerative disorders)\u3001\u708e\u75c7\u6027\u75be\u75c5(inflammatory diseases)\u548c\u5fc3\u8840\u7ba1\u75be\u75c5(cardiovascular diseases)\u3002\u56e0\u6b64\uff0c\u8a31\u591a\u86cb\u767d\u9176\u6291\u5236\u5291\u3010\u5c0f\u5206\u5b50(small molecules)\u548c\u86cb\u767d\u8cea\u3011\u5df2\u88ab\u9451\u5b9a\u70ba\u963b\u65b7\u86cb\u767d\u9176\u7684\u6d3b\u6027(proteases)\u3002\u86cb\u767d\u9176\u6291\u5236\u5291\u53ef\u4ee5\u6839\u64da\u5b83\u5011\u901a\u904e\u5169\u7a2e\u4e00\u822c\u6a5f\u5236\u6291\u5236\u7684\u86cb\u767d\u9176\u985e\u5225\u5206\u70ba\u4e0d\u540c\u7684\u985e\u578b\uff0c\u5373\u4e0d\u53ef\u9006\u7684\u201c\u6355\u7372(trapping)\u201d\u53cd\u61c9\u548c\u53ef\u9006(reversible)\u7684\u7dca\u5bc6\u7d50\u5408\u53cd\u61c9\u3002\u86cb\u767d\u9176\u6291\u5236\u5291\u5df2\u88ab\u7528\u4f5c\u6cbb\u7642\u86cb\u767d\u9176\u76f8\u95dc\u75be\u75c5\u7684\u8a3a\u65b7\u5291(diagnostic)\u6216\u6cbb\u7642\u5291(therapeutic agents)\u3002<\/p>\n

17-DMAG (Alvespimycin) HCl | CAS#467214-21-7 APExBIO\u00a0 \u8ca8\u865fA2213<\/span><\/strong><\/span><\/a><\/span><\/p>\n

\"\"<\/p>\n

Product Citation+3<\/p>\n

Hsp90 inhibitor<\/p>\n

17-DMAG \u662f Hsp90 \u7684\u6291\u5236\u5291\uff0cIC50 \u503c\u70ba 62\u00b129nM [1]\u300217-DMAG \u53ef\u4ee5\u8207 Hsp90 \u7684 ATP \u7d50\u5408\u57fa\u5e8f\u7d50\u5408\uff0c\u6291\u5236 Hsp90 \u7684\u86cb\u767dchaperoning\u6d3b\u6027\u3002\u5b83\u5c07\u5c0e\u81f4 Hsp90 \u7684client proteins\uff08\u5982 EGFR\u3001AKT\u3001\u7a81\u8b8a p53 \u548c IKK\uff09\u7684\u932f\u8aa4\u6298\u758a(misfolding)\u548c\u96a8\u5f8c\u7684\u964d\u89e3(degradation) \u3002\u7531\u65bc\u816b\u7624\u7d30\u80de\u4e2d 17-DMAG \u7d50\u5408\u6240\u9700\u7684 Hsp90 \u5177\u6709\u66f4\u7279\u7570\u6027\u7684conformation\uff0c\u4e26\u4e14 Hsp90 \u7684\u8a31\u591aclient proteins\u6709\u52a9\u65bc\u816b\u7624\u7d30\u80de\u7684\u751f\u9577\uff0c\u56e0\u6b64 17-DMAG \u5c0d\u816b\u7624\u7d30\u80de\u7684\u6bd2\u6027\u901a\u5e38\u6bd4\u5c0d\u6b63\u5e38\u7d30\u80de\u7684\u6bd2\u6027\u66f4\u5927 [2]\u3002\u64da\u5831\u5c0e\uff0c17-DMAG \u662f\u4e00\u7a2e\u6297\u816b\u7624\u5291(ntitumor agent)\uff0c\u5728\u9ad4\u5916\u548c\u521d\u59cb\u9ad4\u5167\u8a66\u9a57\u4e2d\u5177\u6709\u66f4\u5ee3\u6cdb\u7684\u53ef\u5229\u7528\u6d3b\u6027\u548c\u85e5\u5b78\u4e0a\u66f4\u6613\u65bc\u8655\u7406\u7684\u7279\u5fb5\u3002 17-DMAG\u5728\u8655\u7406NCI 60\u7d30\u80de\u682a\u6642\u53ef\u5f71\u97ff\u7d30\u80de\u751f\u9577\uff0c\u5e73\u5747GI50\u70ba0.053mM\u3002 17-DMAG \u7684\u9ad4\u5167\u6d3b\u6027\u5728\u56db\u500b\u9ed1\u8272\u7d20\u7624\u6a21\u578b\u4e2d\u4f7f\u7528 Freiburg \u4eba\u985e\u816b\u7624\u7570\u7a2e\u79fb\u690d\u7d44\u548c\u5169\u500b\u80ba\u7570\u7a2e\u79fb\u690d(lung xenografts)\u9032\u884c\u4e86\u6e2c\u8a66\u3002\u5b83\u8868\u660e 17-DMAG \u5728\u5169\u500b\u80ba\u7570\u7a2e\u79fb\u690d\u7269\u548c\u56db\u500b\u9ed1\u8272\u7d20\u7624\u6a21\u578b\u4e2d\u7684\u5169\u500b\u4e2d\u5177\u6709\u9ad8\u6d3b\u6027\uff0c\u4f46\u5728\u53e6\u5916\u5169\u500b MEXF 462 \u548c MEXF 514 \u4e2d\u6c92\u6709 [3]\u3002<\/p>\n

\"\"<\/p>\n

    \n
  1. Peng Zhou, Becky K.C. Chan, et al. “A Three-Way Combinatorial CRISPR Screen for Analyzing Interactions among Druggable Targets.” Cell Rep. 2020 Aug 11;32(6):108020.PMID:32783942<\/a><\/li>\n
  2. Bhola PD, Ahmed E, et al. “High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors.” Sci Signal. 2020;13(636):eaay1451.PMID:32546544<\/a><\/li>\n
  3. Katayama K, Noguchi K, et al. “Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia.” Oncotarget. 2018 Sep 28;9(76):34240-34258.PMID:30344940<\/a><\/li>\n<\/ol>\n

    \"\"<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Physical Appearance<\/td>\nA solid<\/td>\n<\/tr>\n
    Storage<\/td>\nStore at -20\u00b0C<\/td>\n<\/tr>\n
    M.Wt<\/td>\n653.21<\/td>\n<\/tr>\n
    Cas No.<\/td>\n467214-21-7<\/td>\n<\/tr>\n
    Formula<\/td>\nC32<\/sub>H48<\/sub>N4<\/sub>O8<\/sub>\u00b7HCl<\/td>\n<\/tr>\n
    Solubility<\/td>\n\u226526.2 mg\/mL in DMSO; insoluble in EtOH; \u22653.04 mg\/mL in H2O<\/td>\n<\/tr>\n
    Chemical Name<\/td>\n[(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-21-[2-(dimethylamino)ethylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate;hydrochloride<\/td>\n<\/tr>\n
    SDF<\/td>\nDownload SDF<\/a><\/td>\n<\/tr>\n
    Canonical SMILES<\/td>\nCC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)C)OC)OC(=O)N)C)C)O)OC.Cl<\/td>\n<\/tr>\n
    Shipping Condition<\/td>\nShip with blue ice, or upon other requests.<\/td>\n<\/tr>\n
    General tips<\/td>\nFor obtaining a higher solubility, please warm the tube at 37\u00b0C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

     <\/p>\n

    <\/p>\n

    APExBIO\u53f0\u7063\u4ee3\u7406\u5546:\u00a0 <\/span><\/span><\/strong><\/span><\/a>https:\/\/www.apexbt.com\/<\/span><\/span><\/a><\/span><\/p>\n

    APExBIO\u63d0\u4f9b\u512a\u8cea\u7684\u80dc\u80bd\u548c\u751f\u7269\u5206\u6790\u8a66\u5291\uff0c\u5ee3\u6cdb\u7522\u54c1\u7dda\u5982Protease\u3001Chromatin\/Epigenetics\u8868\u89c0\u907a\u50b3\u5b78\u3001MAPK Signal\u3001DNA Damege\/DNA repair\u3001\u7d30\u80de\u51cb\u4ea1\u3001\u816b\u7624\u751f\u7269\u5b78\u3001Stem cell\u7b49\u7814\u7a76\u9818\u57df\uff0c \u9084\u63d0\u4f9b\u5b9a\u5236\u7684\u670d\u52d9\uff0c\u5305\u62ec\u591a\u80bd\u5408\u6210\uff0c\u6297\u9ad4\u7684\u751f\u7522\u548c\u6aa2\u6e2c\u7684\u767c\u5c55\u3002\u7522\u54c1\u7ddaDNA\/RNA prep kit\u3001Drug Screening panel\u3001Bioactive peptides\u3001Growth factors\u3001Biotinylation Reagents\u3001tag peptides\u3001amino Acids\u3001Growth factors\u7b49\u3002APExBIO\u7522\u54c1\u8cea\u91cf\u90fd\u4f34\u96a8\u8457\u8b49\u66f8\u7684\u5206\u6790\uff0c\u9ad8\u6548\u6db2\u76f8\u8272\u8b5c\uff0c\u8cea\u8b5c\uff0c\u548cHMNR\u6578\u64da\u3002<\/p>\n

    <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    A4324<\/td>\nPioglitazone HCl<\/td>\n112529-15-4<\/td>\n99.35%<\/td>\nPPAR\u03b3 agonist<\/td>\n<\/tr>\n
    A4325<\/td>\nPF-2545920<\/td>\n1292799-56-4<\/td>\n99.90%<\/td>\nPDE10A inhibitor,potent and selective<\/td>\n<\/tr>\n
    A4326<\/td>\nTAK-700 (Orteronel)<\/td>\n426219-18-3<\/td>\n99.44%<\/td>\nHuman 17,20-lyase inhibitor<\/td>\n<\/tr>\n
    A4327<\/td>\nTadalafil<\/td>\n171596-29-5<\/td>\n99.91%<\/td>\nPDE5 inhibitor<\/td>\n<\/tr>\n
    A4328<\/td>\nRolipram<\/td>\n61413-54-5<\/td>\n98.19%<\/td>\nPDE4-inhibitor and an anti-inflammatory agent<\/td>\n<\/tr>\n
    A4329<\/td>\nCilomilast<\/td>\n153259-65-5<\/td>\n99.37%<\/td>\nPotent PDE4 inhibitor<\/td>\n<\/tr>\n
    A4330<\/td>\nIsotretinoin<\/td>\n4759-48-2<\/td>\n99.89%<\/td>\nDopamine \u03b2-hydroxylase activator<\/td>\n<\/tr>\n
    A4331<\/td>\nGSK256066<\/td>\n801312-28-7<\/td>\n98.39%<\/td>\nPDE4-inhibitor,selective and highly potent<\/td>\n<\/tr>\n
    A4332<\/td>\nNepicastat (SYN-117) HCl<\/td>\n170151-24-3<\/td>\n98.14%<\/td>\nDopamine-\u03b2-hydroxylase inhibitor<\/td>\n<\/tr>\n
    A4333<\/td>\nCPI-613<\/td>\n95809-78-2<\/td>\n99.45%<\/td>\nPDH\/\u03b1-KGDH inhibitor<\/td>\n<\/tr>\n
    A4334<\/td>\nAvanafil<\/td>\n330784-47-9<\/td>\n99.07%<\/td>\nPDE5 inhibitor<\/td>\n<\/tr>\n
    A4335<\/td>\nMildronate<\/td>\n76144-81-5<\/td>\n98.33%<\/td>\nGBB hydroxylase inhibitor<\/td>\n<\/tr>\n
    A4336<\/td>\nMycophenolate Mofetil<\/td>\n128794-94-5<\/td>\n99.67%<\/td>\nIMPDH inhibitor<\/td>\n<\/tr>\n
    A4337<\/td>\nCilostazol<\/td>\n73963-72-1<\/td>\n99.94%<\/td>\nPDE3 inhibitor<\/td>\n<\/tr>\n
    A4338<\/td>\nRivaroxaban<\/td>\n366789-02-8<\/td>\n99.91%<\/td>\nFactor Xa inhibitor<\/td>\n<\/tr>\n
    A4339<\/td>\nAGI-5198<\/td>\n1355326-35-0<\/td>\n97.43%<\/td>\nIDH1 inhibitor against R132 mutant,selective and cell-permeable<\/td>\n<\/tr>\n
    A4340<\/td>\nPimobendan<\/td>\n74150-27-9<\/td>\n99.25%<\/td>\nSelective PDE3 inhibitor.Ca2+ channel sensitizer<\/td>\n<\/tr>\n
    A4341<\/td>\nApixaban<\/td>\n503612-47-3<\/td>\n99.87%<\/td>\nFactor Xa inhibitor<\/td>\n<\/tr>\n
    A4342<\/td>\nGimeracil<\/td>\n103766-25-2<\/td>\n99.82%<\/td>\nDihydropyrimidine dehydrogenase inhibitor<\/td>\n<\/tr>\n
    A4343<\/td>\nDyphylline<\/td>\n479-18-5<\/td>\n99.84%<\/td>\nPan-PDE inhibitor<\/td>\n<\/tr>\n
    A4344<\/td>\nOzagrel<\/td>\n82571-53-7<\/td>\n99.84%<\/td>\nThromboxane A2 synthetase inhibitor<\/td>\n<\/tr>\n
    A4345<\/td>\nMK-8245<\/td>\n1030612-90-8<\/td>\n99.76%<\/td>\nSCD inhibitor,potent and liver-selective<\/td>\n<\/tr>\n
    A4346<\/td>\nAminophylline<\/td>\n317-34-0<\/td>\n99.05%<\/td>\nPan-PDE inhibitor<\/td>\n<\/tr>\n
    A4347<\/td>\nMethotrexate<\/td>\n59-05-2<\/td>\n99.14%<\/td>\nFolate antagonist,inhibits DFHR<\/td>\n<\/tr>\n
    A4348<\/td>\nTrilostane<\/td>\n13647-35-3<\/td>\n99.58%<\/td>\n3\u03b2-HSD inhibitor<\/td>\n<\/tr>\n
    A4349<\/td>\nS- (+)-Rolipram<\/td>\n85416-73-5<\/td>\n99.93%<\/td>\nCAMP-specific PDE4 inhibitor<\/td>\n<\/tr>\n
    A4350<\/td>\nPralatrexate<\/td>\n146464-95-1<\/td>\n98.47%<\/td>\nAntifolate,a folate analog<\/td>\n<\/tr>\n
    A4351<\/td>\nPluriSIn #1 (NSC 14613)<\/td>\n91396-88-2<\/td>\n99.32%<\/td>\nSCD1 inhibitor<\/td>\n<\/tr>\n
    A4352<\/td>\nAnagrelide HCl<\/td>\n58579-51-4<\/td>\n99.62%<\/td>\nThrombocytopenic agent<\/td>\n<\/tr>\n
    A4353<\/td>\nPyrimethamine<\/td>\n58-14-0<\/td>\n99.65%<\/td>\nDHFR inhibitor<\/td>\n<\/tr>\n
    A4354<\/td>\nUK 383367<\/td>\n348622-88-8<\/td>\n98.00%<\/td>\nBMP-1\/PCP inhibitor,potent and selective<\/td>\n<\/tr>\n
    A4355<\/td>\nTosedostat (CHR2797)<\/td>\n238750-77-1<\/td>\n98.96%<\/td>\nAminopeptidase inhibitor<\/td>\n<\/tr>\n
    A4356<\/td>\nVarespladib (LY315920)<\/td>\n172732-68-2<\/td>\n98.00%<\/td>\nHnsPLA inhibitor,potent and selective<\/td>\n<\/tr>\n
    A4357<\/td>\nDorzolamide HCl<\/td>\n130693-82-2<\/td>\n99.87%<\/td>\nCarbonic anhydrase inhibitor<\/td>\n<\/tr>\n
    A4358<\/td>\nU-104<\/td>\n178606-66-1<\/td>\n99.82%<\/td>\nCAIX inhibitor<\/td>\n<\/tr>\n
    A4359<\/td>\nBrinzolamide<\/td>\n138890-62-7<\/td>\n99.88%<\/td>\nCA II inhibitor<\/td>\n<\/tr>\n
    A4360<\/td>\nTopiramate<\/td>\n97240-79-4<\/td>\n100.00%<\/td>\nGluR5 receptor antagonist,anticonvulsant<\/td>\n<\/tr>\n
    A4361<\/td>\nJNJ-1661010<\/td>\n681136-29-8<\/td>\n98.00%<\/td>\nFAAH inhibitor,potent and selective<\/td>\n<\/tr>\n
    A4362<\/td>\nTioxolone<\/td>\n4991-65-5<\/td>\n98.67%<\/td>\nCAI inhibitor<\/td>\n<\/tr>\n
    A4363<\/td>\nFluvastatin Sodium<\/td>\n93957-55-2<\/td>\n98.84%<\/td>\nHMG-CoA reductase inhibitor<\/td>\n<\/tr>\n
    A4364<\/td>\nMethazolamide<\/td>\n554-57-4<\/td>\n99.79%<\/td>\nCarbonic anhydrase inhibitor<\/td>\n<\/tr>\n
    A4365<\/td>\nLovastatin<\/td>\n75330-75-5<\/td>\n98.58%<\/td>\nHMG-CoA reductase inhibitor<\/td>\n<\/tr>\n
    A4366<\/td>\nRasagiline Mesylate<\/td>\n161735-79-1<\/td>\n99.23%<\/td>\nIrreversible MAO-B inhibitor<\/td>\n<\/tr>\n
    A4367<\/td>\nAtorvastatin Calcium<\/td>\n134523-03-8<\/td>\n99.76%<\/td>\nHMG-CoA reductase inhibitor<\/td>\n<\/tr>\n
    A4368<\/td>\nSafinamide Mesylate<\/td>\n202825-46-5<\/td>\n98.60%<\/td>\nMAO-B inhibitor,potent,selective and reversible<\/td>\n<\/tr>\n
    A4369<\/td>\nPravastatin sodium<\/td>\n81131-70-6<\/td>\n98.00%<\/td>\nHMG-CoA reductase inhibitor,highly selective and competitive<\/td>\n<\/tr>\n
    A4370<\/td>\nMoclobemide (Ro 111163)<\/td>\n71320-77-9<\/td>\n99.85%<\/td>\nReversible inhibitor of MAO-A<\/td>\n<\/tr>\n
    A4371<\/td>\nFerrostatin-1 (Fer-1)<\/td>\n347174-05-4<\/td>\n99.75%<\/td>\nFerroptosis inhibitor, erastin-induced<\/td>\n<\/tr>\n
    A4372<\/td>\nURB597<\/td>\n546141-08-6<\/td>\n99.58%<\/td>\nFAAH inhibitor,potent and selective<\/td>\n<\/tr>\n
    A4373<\/td>\nNLG919<\/td>\n1402836-58-1<\/td>\n99.79%<\/td>\nPotent IDO pathway inhibitor<\/td>\n<\/tr>\n
    A4374<\/td>\nPF-3845<\/td>\n1196109-52-0<\/td>\n98.00%<\/td>\nFAAH ihibitor,highly potent and selective<\/td>\n<\/tr>\n
    A4375<\/td>\nAnacetrapib (MK-0859)<\/td>\n875446-37-0<\/td>\n99.76%<\/td>\nRhCETP\/mutant CETP(C13S) inhibitor<\/td>\n<\/tr>\n
    A4376<\/td>\nDalcetrapib (JTT-705, RO4607381)<\/td>\n211513-37-0<\/td>\n98.00%<\/td>\nrhCETP inhibitor<\/td>\n<\/tr>\n
    A4377<\/td>\nEvacetrapib (LY2484595)<\/td>\n1186486-62-3<\/td>\n98.83%<\/td>\nCETP inhibitor,potent and selective<\/td>\n<\/tr>\n
    A4378<\/td>\nTorcetrapib<\/td>\n262352-17-0<\/td>\n98.00%<\/td>\nCETP inhibitor<\/td>\n<\/tr>\n
    A4379<\/td>\nLonafarnib<\/td>\n193275-84-2<\/td>\n98.00%<\/td>\nFtase inhibitor,potent and selective<\/td>\n<\/tr>\n
    A4381<\/td>\nFK866 (APO866)<\/td>\n658084-64-1<\/td>\n99.58%<\/td>\nNAMPT inhibitor, non-competitive, highly specific<\/td>\n<\/tr>\n
    A4382<\/td>\nA922500<\/td>\n959122-11-3<\/td>\n97.62%<\/td>\nDGAT-1 inhibitor<\/td>\n<\/tr>\n
    A4383<\/td>\nTolcapone<\/td>\n134308-13-7<\/td>\n99.42%<\/td>\nCOMT inhibitor<\/td>\n<\/tr>\n
    A4384<\/td>\nPF-04620110<\/td>\n1109276-89-2<\/td>\n98.00%<\/td>\nDGAT-1 inhibitor,potent and selective<\/td>\n<\/tr>\n
    A4385<\/td>\nGanetespib (STA-9090)<\/td>\n888216-25-9<\/td>\n99.03%<\/td>\nHsp90 inhibitor,non-geldanamycin<\/td>\n<\/tr>\n
    A4386<\/td>\nElesclomol (STA-4783)<\/td>\n488832-69-5<\/td>\n98.00%<\/td>\nOxidative stress\/apoptosis inducer,potent and novel<\/td>\n<\/tr>\n
    A4387<\/td>\nVER 155008<\/td>\n1134156-31-2<\/td>\n99.72%<\/td>\nHSP 70 inhibitor,adenosine-derived<\/td>\n<\/tr>\n
    A4388<\/td>\nXL-888<\/td>\n1149705-71-4<\/td>\n98.00%<\/td>\nHsp90 inhibitor<\/td>\n<\/tr>\n
    A4390<\/td>\nPemetrexed<\/td>\n150399-23-8<\/td>\n99.88%<\/td>\nTS, DHFR,GARFT and AICARFT inhibitor<\/td>\n<\/tr>\n
    A4393<\/td>\nPaclitaxel (Taxol)<\/td>\n33069-62-4<\/td>\n99.71%<\/td>\nAntineoplastic agent<\/td>\n<\/tr>\n
    A4394<\/td>\nDocetaxel<\/td>\n114977-28-5<\/td>\n98.56%<\/td>\nMicrotubulin disassembly inhibitor<\/td>\n<\/tr>\n
    A4395<\/td>\n10-DAB (10-Deacetylbaccatin)<\/td>\n32981-86-5<\/td>\n98.26%<\/td>\nPrecursor of antitumor compound Palitaxel and Docetaxel<\/td>\n<\/tr>\n
    A4400<\/td>\nBMS 299897<\/td>\n290315-45-6<\/td>\n98.00%<\/td>\n\u03b3–secretase inhibitor, potent and orally active<\/td>\n<\/tr>\n
    A4401<\/td>\nCompound W<\/td>\n173550-33-9<\/td>\n98.00%<\/td>\n\u03b3-secretase inhibitor<\/td>\n<\/tr>\n
    A4402<\/td>\nFlurizan<\/td>\n51543-40-9<\/td>\n99.76%<\/td>\nNSAID,inhibits \u03b3-secretase activity<\/td>\n<\/tr>\n
    A4403<\/td>\nJLK 6<\/td>\n62252-26-0<\/td>\n98.00%<\/td>\n\u03b3-secretase inhibitor<\/td>\n<\/tr>\n
    A4404<\/td>\nL-685,458<\/td>\n292632-98-5<\/td>\n99.25%<\/td>\n\u03b3-secretase inhibitor<\/td>\n<\/tr>\n
    A4405<\/td>\nMRK 560<\/td>\n677772-84-8<\/td>\n98.00%<\/td>\n\u03b3-secretase inhibitor<\/td>\n<\/tr>\n
    A4406<\/td>\nBegacestat<\/td>\n769169-27-9<\/td>\n98.00%<\/td>\n\u03b3-secretase inhibitor<\/td>\n<\/tr>\n
    A4407<\/td>\nFumagillin<\/td>\n23110-15-8<\/td>\n98.00%<\/td>\nAntibiotic and antiangiogenic agent<\/td>\n<\/tr>\n
    A4408<\/td>\nSC 57461A<\/td>\n423169-68-0<\/td>\n98.00%<\/td>\nLTA4 hydrolase inhibitor,potent and selective<\/td>\n<\/tr>\n
    A4409<\/td>\nSpinorphin<\/td>\n137201-62-8<\/td>\n98.00%<\/td>\nP2X3 receptors against<\/td>\n<\/tr>\n
    A4410<\/td>\nAcetyl-Calpastatin (184-210) (human)<\/td>\n123714-50-1<\/td>\n98.00%<\/td>\nCalpain I\/II inhibitor<\/td>\n<\/tr>\n
    A4411<\/td>\nCalpeptin<\/td>\n117591-20-5<\/td>\n98.00%<\/td>\nCa2+-dependent protease,calpain inhibitor<\/td>\n<\/tr>\n
    A4412<\/td>\nMDL 28170<\/td>\n88191-84-8<\/td>\n98.00%<\/td>\nCalpain and cathepsin B inhibitor, selective<\/td>\n<\/tr>\n
    A4413<\/td>\nPD 150606<\/td>\n179528-45-1<\/td>\n98.00%<\/td>\nNon-peptide calpain inhibitor<\/td>\n<\/tr>\n
    A4414<\/td>\nPMPA (NAALADase inhibitor)<\/td>\n173039-10-6<\/td>\n98.00%<\/td>\nGlutamate carboxypeptidase 2 inhibitor<\/td>\n<\/tr>\n
    A4415<\/td>\nZJ 43<\/td>\n723331-20-2<\/td>\n98.00%<\/td>\nGCP II and III\/NAAG peptidase\/NAALADase inhibitor<\/td>\n<\/tr>\n
    A4416<\/td>\nAZ 10417808<\/td>\n331645-84-2<\/td>\n98.00%<\/td>\nCaspase-3 inhibitor,selective non-peptide<\/td>\n<\/tr>\n
    A4417<\/td>\nIvachtin<\/td>\n745046-84-8<\/td>\n98.00%<\/td>\nCaspase-3 inhibitor<\/td>\n<\/tr>\n
    A4418<\/td>\nAc-IEPD-AFC<\/td>\n1135417-31-0<\/td>\n96.06%<\/td>\nRecognition motif for serine protease granzyme B<\/td>\n<\/tr>\n
    A4419<\/td>\nAc-LEHD-AFC<\/td>\n210345-03-2<\/td>\n\u226595.00%<\/td>\nFluorogenic caspase substrate<\/td>\n<\/tr>\n
    A4420<\/td>\nPETCM<\/td>\n10129-56-3<\/td>\n98.00%<\/td>\nCaspase-3 activator<\/td>\n<\/tr>\n
    A4422<\/td>\nL 006235<\/td>\n294623-49-7<\/td>\n98.00%<\/td>\nCathepsin K inhibitor<\/td>\n<\/tr>\n
    A4424<\/td>\nSID 26681509<\/td>\n958772-66-2<\/td>\n98.00%<\/td>\nHuman cathepsin L inhibitor,potent and reversible<\/td>\n<\/tr>\n
    A4425<\/td>\nDPPI 1c hydrochloride<\/td>\n866396-34-1<\/td>\n98.00%<\/td>\nDPP-IV Inhibitor<\/td>\n<\/tr>\n
    A4426<\/td>\nK 579<\/td>\n440100-64-1<\/td>\n98.00%<\/td>\nDipeptidyl peptidase IV inhibitor<\/td>\n<\/tr>\n
    A4427<\/td>\nNVP DPP 728 dihydrochloride<\/td>\n247016-69-9<\/td>\n96.76%<\/td>\nDPP-IV inhibitor<\/td>\n<\/tr>\n
    A4428<\/td>\nPK 44 phosphate<\/td>\n1017682-65-3<\/td>\n98.00%<\/td>\nDPP-IV inhibitor<\/td>\n<\/tr>\n
    A4429<\/td>\nVialinin A<\/td>\n858134-23-3<\/td>\n98.00%<\/td>\nUSP\/isopeptidase T (IsoT)\/UCH-L1 DUB inhibitor<\/td>\n<\/tr>\n
    A4430<\/td>\nSivelestat sodium salt<\/td>\n150374-95-1<\/td>\n98.00%<\/td>\nLeukocyte elastase inhibitor<\/td>\n<\/tr>\n
    A4431<\/td>\nSSR 69071<\/td>\n344930-95-6<\/td>\n\u226595.00%<\/td>\nHLE inhibitor<\/td>\n<\/tr>\n
    A4432<\/td>\nARP 100<\/td>\n704888-90-4<\/td>\n98.00%<\/td>\nSelective MMP-2 inhibitor<\/td>\n<\/tr>\n
    A4433<\/td>\nARP 101<\/td>\n849773-63-3<\/td>\n98.00%<\/td>\nMMP inhibitor,potent and selective<\/td>\n<\/tr>\n
    A4434<\/td>\nCL 82198 hydrochloride<\/td>\n307002-71-7<\/td>\n98.00%<\/td>\nSelective MMP-13 inhibitor<\/td>\n<\/tr>\n
    A4435<\/td>\nCP 471474<\/td>\n210755-45-6<\/td>\n98.00%<\/td>\nBroad spectrum MMP inhibitor<\/td>\n<\/tr>\n
    A4436<\/td>\nGI 254023X<\/td>\n260264-93-5<\/td>\n98.00%<\/td>\nSelective inhibitor of ADAM10 metalloprotease<\/td>\n<\/tr>\n
    A4437<\/td>\nONO 4817<\/td>\n223472-31-9<\/td>\n98.00%<\/td>\nMMP inhibitor<\/td>\n<\/tr>\n
    A4438<\/td>\nPD 166793<\/td>\n199850-67-4<\/td>\n98.00%<\/td>\nMMP inhibitor<\/td>\n<\/tr>\n
    A4440<\/td>\nUK 356618<\/td>\n230961-08-7<\/td>\n98.00%<\/td>\nMMP-3 inhibitor,potent and selective<\/td>\n<\/tr>\n
    A4441<\/td>\nUK 370106<\/td>\n230961-21-4<\/td>\n98.00%<\/td>\nMMP-3\/MMP-12 Inhiibitor,highly selective<\/td>\n<\/tr>\n
    A4442<\/td>\nWAY 170523<\/td>\n307002-73-9<\/td>\n98.00%<\/td>\nMMP-13 inhibitor,potent and selective<\/td>\n<\/tr>\n
    A4443<\/td>\nGliotoxin<\/td>\n67-99-2<\/td>\n98.00%<\/td>\n20S proteasome inhibitor<\/td>\n<\/tr>\n
    A4444<\/td>\nBC 11 hydrobromide<\/td>\n443776-49-6<\/td>\n98.00%<\/td>\nSelective urokinase inhibitor<\/td>\n<\/tr>\n
    A4445<\/td>\n4-Chlorophenylguanidine hydrochloride<\/td>\n14279-91-5<\/td>\n98.00%<\/td>\nUrokinase inhibitor, potent and specific<\/td>\n<\/tr>\n
    A4446<\/td>\nR18<\/td>\n211364-78-2<\/td>\n98.00%<\/td>\n14.3.3 proteins Antagonist<\/td>\n<\/tr>\n
    A4447<\/td>\n2,3-DCPE hydrochloride<\/td>\n418788-90-6<\/td>\n98.00%<\/td>\nBcl-XL protein expression downregulator<\/td>\n<\/tr>\n
    A4448<\/td>\nActinomycin D<\/td>\n50-76-0<\/td>\n98.00%<\/td>\nRNA polymerase inhibitor<\/td>\n<\/tr>\n
    A4449<\/td>\nC 75<\/td>\n191282-48-1<\/td>\n98.00%<\/td>\nFatty acid synthase (FAS) inhibitor<\/td>\n<\/tr>\n
    A4450<\/td>\nCHM 1<\/td>\n154554-41-3<\/td>\n98.00%<\/td>\nTubulin polymerization inhibitor<\/td>\n<\/tr>\n
    A4451<\/td>\nDeguelin<\/td>\n522-17-8<\/td>\n98.00%<\/td>\nAnticancer and antiviral agent<\/td>\n<\/tr>\n
    A4452<\/td>\nMitomycin C<\/td>\n50-07-7<\/td>\n98.00%<\/td>\nInhibits DNA synthesis,antibiotic and antitumor agent<\/td>\n<\/tr>\n
    A4453<\/td>\nNSC 687852 (b-AP15)<\/td>\n1009817-63-3<\/td>\n98.15%<\/td>\n19S regulatory particle Inhibitor<\/td>\n<\/tr>\n
    A4454<\/td>\nOncrasin 1<\/td>\n75629-57-1<\/td>\n98.00%<\/td>\nProapoptotic agent<\/td>\n<\/tr>\n
    A4455<\/td>\nPiperlongumine<\/td>\n20069-09-4<\/td>\n98.00%<\/td>\nInducer of cell-death<\/td>\n<\/tr>\n
    A4456<\/td>\nPlumbagin<\/td>\n481-42-5<\/td>\n98.00%<\/td>\nAnticancer agent<\/td>\n<\/tr>\n
    A4457<\/td>\nStreptozocin<\/td>\n18883-66-4<\/td>\n98.00%<\/td>\nAntibiotic and antitumor agent<\/td>\n<\/tr>\n
    A4458<\/td>\nARRY 520 trifluoroacetate<\/td>\n885060-09-3<\/td>\n98.00%<\/td>\nKSP inhibitor<\/td>\n<\/tr>\n
    A4459<\/td>\nBax channel blocker<\/td>\n335165-68-9<\/td>\n98.00%<\/td>\nInhibitor of Bax-mediated mitochondrial cytochrome c release<\/td>\n<\/tr>\n
    A4460<\/td>\nBax inhibitor peptide P5<\/td>\n579492-83-4<\/td>\n99.59%<\/td>\nBax inhibitor<\/td>\n<\/tr>\n
    A4461<\/td>\nBax inhibitor peptide V5<\/td>\n579492-81-2<\/td>\n99.19%<\/td>\nBax inhibitor<\/td>\n<\/tr>\n
    A4463<\/td>\nBIM, Biotinylated<\/td>\n<\/td>\n99.04%<\/td>\nBim peptide fragment with a biotin moiety attached<\/td>\n<\/tr>\n
    A4465<\/td>\nMIM1<\/td>\n509102-00-5<\/td>\n98.69%<\/td>\nMcl-1 Inhibitor<\/td>\n<\/tr>\n
    A4466<\/td>\nMuristerone A<\/td>\n38778-30-2<\/td>\n\u226595.00%<\/td>\nTRAIL- and hFasL-induced apoptosis inhibitor<\/td>\n<\/tr>\n
    A4467<\/td>\nSU 9516<\/td>\n377090-84-1<\/td>\n98.00%<\/td>\nCdk2 inhibitor<\/td>\n<\/tr>\n
    A4468<\/td>\nCesium chloride<\/td>\n7647-17-8<\/td>\n98.00%<\/td>\nPotassium channel blocker<\/td>\n<\/tr>\n
    A4469<\/td>\nDAPK Substrate Peptide<\/td>\n386769-53-5<\/td>\n98.00%<\/td>\nSynthetic peptide substrate for DAPK<\/td>\n<\/tr>\n
    A4471<\/td>\nGRI 977143<\/td>\n325850-81-5<\/td>\n98.00%<\/td>\nLPA2 receptor non-lipid agonist<\/td>\n<\/tr>\n
    A4472<\/td>\nMdivi 1<\/td>\n338967-87-6<\/td>\n99.52%<\/td>\nSelective DRP1\/Dnm1 inhibitor, cell-permeable<\/td>\n<\/tr>\n
    A4473<\/td>\nMelphalan<\/td>\n148-82-3<\/td>\n98.00%<\/td>\nDNA alkylating agent<\/td>\n<\/tr>\n
    A4474<\/td>\nNQDI 1<\/td>\n175026-96-7<\/td>\n98.00%<\/td>\nASK1, MAP3K5 inhibitor<\/td>\n<\/tr>\n
    A4475<\/td>\nTLQP 21<\/td>\n869988-94-3<\/td>\n98.00%<\/td>\nVGF-derived peptide<\/td>\n<\/tr>\n
    A4476<\/td>\nCP 31398 dihydrochloride<\/td>\n1217195-61-3<\/td>\n98.00%<\/td>\np53 stabilizer<\/td>\n<\/tr>\n
    A4477<\/td>\nCyclic Pifithrin-\u03b1 hydrobromide<\/td>\n511296-88-1<\/td>\n99.34%<\/td>\nP53 inhibitor<\/td>\n<\/tr>\n
    A4478<\/td>\nHLI 373<\/td>\n502137-98-6<\/td>\n98.00%<\/td>\nHdm2 ubiquitin ligase (E3) inhibitor<\/td>\n<\/tr>\n
    A4479<\/td>\nMIRA-1<\/td>\n72835-26-8<\/td>\n98.00%<\/td>\nRestorer of wild-type p53 conformation\/cellular function<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

     <\/p>\n","protected":false},"excerpt":{"rendered":"

    \u86cb\u767d\u9176(Proteases)\u7cfb\u5217\u5546\u54c1->>17-DMAG (Alvespimycin) HCl A […]<\/p>\n","protected":false},"author":3,"featured_media":34308,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5368,486],"tags":[4959],"_links":{"self":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/34314"}],"collection":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34314"}],"version-history":[{"count":7,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/34314\/revisions"}],"predecessor-version":[{"id":53800,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/34314\/revisions\/53800"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/34308"}],"wp:attachment":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34314"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}